Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Cellivery Therapeutics Inc patents


Recent patent applications related to Cellivery Therapeutics Inc. Cellivery Therapeutics Inc is listed as an Agent/Assignee. Note: Cellivery Therapeutics Inc may have other listings under different names/spellings. We're not affiliated with Cellivery Therapeutics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Cellivery Therapeutics Inc-related inventors


 new patent  Cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof

The icp-rf recombinant protein of present invention could mediate generation of the induced pluripotent stem cells (ipscs) from terminally differentiated somatic cells.. . ... Cellivery Therapeutics Inc

Improved cell-permeable (icp) parkin recombinant protein and use thereof

Disclosed are improved cell-permeable parkin recombinant proteins (icp-parkin) which have been developed as a protein-based anti-neurodegenerative agent for efficient bbb-penetration to effectively deliver the recombinant protein into the brain. A parkin protein, a dopaminergic neuronal cell death inhibitor, has been fused with a newly developed advanced macromolecule transduction domain (amtd) and preferably with a solubilization domain (sd) to increase the solubility/yield and cell-/tissue-permeability of the recombinant protein. ... Cellivery Therapeutics Inc

Cell-permeable (icp)-socs3 recombinant protein and uses thereof

The present invention relates to providing improved cell-permeable (icp)-socs3 recombinant protein and uses thereof. Preferably, the icp-socs3 recombinant protein may be used as protein-based anti-angiogenic agent by utilizing the platform technology for macromolecule intracellular transduction.. ... Cellivery Therapeutics Inc

Advanced macromolecule transduction domain (amtd) sequences for improvement of cell-permeability, polynucleotides encoding the same, method to identify the unique features of amtds comprising the same, method to develop the amtd sequences comprising the same

The present invention is to execute macromolecule intracellular transduction technology (mitt) for delivering biologically active macromolecules into the cells; specifically, by exploiting well-enhanced hydrophobic cell penetrating peptide (cpp)—advanced macromolecule transduction domain (amtd)—to effectively transduce biologically active molecules into the plasma membrane, polynucleotides encoding the same, methods of identifying the same, systems of genetically engineering a biologically active molecule with much enhanced cell-permeability by using the same, methods of importing a biologically active molecule into a cell by using the same, and uses thereof.. . ... Cellivery Therapeutics Inc

Cell-permeable (icp)-socs3 recombinant protein and uses thereof

The present invention relates to providing improved cell-permeable (icp)-socs3 recombinant protein and uses thereof. Preferably, the icp-socs3 recombinant protein may be used as protein-based anti-hepatocellular carcinoma (hcc) agent by utilizing the platform technology for macromolecule intracellular transduction.. ... Cellivery Therapeutics Inc

Cell-permeable (icp)-socs3 recombinant protein and uses thereof

The present invention relates to providing improved cell-permeable (icp)-socs3 recombinant protein and uses thereof. Preferably, the icp-socs3 recombinant protein may be used as protein-based anti-lung cancer agent by utilizing the platform technology for macromolecule intracellular transduction.. ... Cellivery Therapeutics Inc

Cell-permeable (icp)-socs3 recombinant protein and uses thereof

The present invention relates to providing improved cell-permeable (icp)-socs3 recombinant protein and uses thereof. Preferably, the icp-socs3 recombinant protein may be used as protein-based anti-pancreatic cancer agent by utilizing the platform technology for macromolecule intracellular transduction.. ... Cellivery Therapeutics Inc

Cell-permeable (icp)-socs3 recombinant protein and uses thereof

The present invention relates to providing improved cell-permeable (icp)-socs3 recombinant protein and uses thereof. Preferably, the icp-socs3 recombinant protein may be used as protein-based anti-solid tumor agent by utilizing the platform technology for macromolecule intracellular transduction.. ... Cellivery Therapeutics Inc

Development of improved cell-permeable (icp) parkin recombinant protein as a protein-based anti-neurodegenerative agent for the treatment of parkinson's disease-associated phenotypes by utilizing bbb-penetrating protein delivery system mitt, enabled by advanced macromolecule transduction domain (amtd)

Macromolecule intracellular transduction technology based on improved cell-permeable parkin recombinant protein (icp-parkin) has been developed as a protein-based anti-neurodegenerative agent for efficient bbb-penetration to effectively deliver the recombinant protein into the brain. Parkin protein, a dopaminergic neuronal cell death inhibitor, has been fused with a newly developed advanced macromolecule transduction domain (amtd) and solubilization domain (sd) to increase the solubility/yield and cell-/tissue-permeability of the recombinant protein. ... Cellivery Therapeutics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Cellivery Therapeutics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cellivery Therapeutics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###